Screener
Capricor Therapeutics CAPR Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Capricor Therapeutics’s 10-K, filed March 17, 2026.
- Filed
- Mar 17, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-029580
| Line item | Years ended December 31, 2025 | Years ended December 31, 2024 |
|---|---|---|
| REVENUE | ||
| Revenue | — | $22,270,465 |
| TOTAL REVENUE | — | 22,270,465 |
| OPERATING EXPENSES | ||
| Research and development | 84,454,595 | 49,968,585 |
| General and administrative | 23,687,535 | 14,865,122 |
| TOTAL OPERATING EXPENSES | 108,142,130 | 64,833,707 |
| LOSS FROM OPERATIONS | (108,142,130) | (42,563,242) |
ITEM 8.FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Capricor Therapeutics's total revenue?
- Capricor Therapeutics (CAPR) reported total revenue of $0 in Q4 2025.
- How has Capricor Therapeutics's total revenue changed year-over-year?
- Capricor Therapeutics's total revenue decreased by 100.0% year-over-year, from $11.13M to $0.
- What is the long-term trend for Capricor Therapeutics's total revenue?
- Over 2 years (2023 to 2025), Capricor Therapeutics's total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $25.18M to $0.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Capricor Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude